


Promising Early Clinical Results**

PATIENT DEMOGRAPHICS



Characteristic (n)	Canada (n=24)		Israel (n=17)		Total
	PANC-101	PANC-02	PANC-02	ALL-00	
Gender					
Male	10	7	6	6	23
Female	14	2	2	2	18
Median Age	70	75	72	72	71
Cancer Stage					
2	4	1	0	0	5
3	4	3	2	2	9
4	16	5	6	6	27
Previous/concurrent lines of chemotherapy					
0	7	1	1	1	9
1	9	3	3	3	15
2	8	5	4	4	17

OVERALL SURVIVAL SUB-POPULATION ANALYSIS



1. Newly Diagnosed / Not Eligible for Chemotherapy (n=8)



2. Metastatic (Stage IV) Patients After 1L FOLFIRINOX (n=10)



3. Progressed After 2L Gemcitabine-Abraxane (n=7)



9 of 10 Patients Median OS Since Alpha DaRT